Using FLT PET imaging to assess cancer in patients
Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
This study is testing a new type of PET imaging to see if it can help doctors better detect cancer and understand how well treatments are working for patients with different kinds of cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | Barbara Ann Karmanos Cancer Institute Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Trial ID | NCT00935090 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography (PET) imaging in patients diagnosed with various types of cancer, including brain tumors and hematologic malignancies. The primary objective is to measure tumor proliferation and the levels of thymidine kinase, which are indicative of DNA synthesis in cancer cells. Additionally, the study aims to determine how well FLT PET imaging can detect cancer lesions and assess patient responses to treatment. Participants will undergo up to four imaging procedures to gather data on the efficacy of this diagnostic method.
Who should consider this trial
Good fit: Ideal candidates include adults with histologically confirmed solid tumors or hematologic malignancies who are awaiting further evaluation.
Not a fit: Patients who are not able to lie still in the PET scanner or those who are pregnant or nursing may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could enhance the ability to diagnose cancer and tailor treatment plans more effectively for patients.
How similar studies have performed: Previous studies using PET imaging for cancer diagnosis have shown promising results, indicating that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS: * Meets one of the following criteria: * Histologically confirmed solid tumor or hematologic malignancy * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging PATIENT CHARACTERISTICS: * Able to lie still in the PET scanner * Girth and weight must be suitable to enter the gantry * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: * Not specified
Where this trial is running
Detroit, Michigan
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Anthony F. Shields, MD, PhD — Barbara Ann Karmanos Cancer Institute
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.